Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system (MARS)

Annals of Hepatology

Volumn 10, Issue SUPPL. 1, 2011, Pages

  Mitzner, Steffen R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin; Hemodynamics; Hepatic encephalopathy; Liver failure

Indexed keywords

ALBUMIN; AMANITA PHALLOIDES TOXIN; CITRIC ACID; HEPARIN; MYCOTOXIN; PARACETAMOL; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ALBUMIN BLOOD LEVEL; ALBUMIN DIALYSIS; ARTICLE; BINDING AFFINITY; BLEEDING; BRAIN EDEMA; BRAIN FUNCTION; CHRONIC LIVER FAILURE; COST BENEFIT ANALYSIS; DRUG OVERDOSE; FATIGUE; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER ISCHEMIA; LIVER REGENERATION; LIVER TRANSPLANTATION; PROTEIN BINDING; PRURITUS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 79956060014     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31602-3     Document Type: Article

References (61)

1. Ho DW, Fan ST, To J, Woo YH, Zhang Z, Lau C, Wong J. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut 2002; 50: 869-876.
2. Ash SR, Carr DJ, Sullivan TA. Sorbent suspension reactor for extracorporeal detoxification in hepatic failure or drug overdose. ASAIO J 2004; 50: lviii-lxv.
3. Vienken J, Christmann H. How can liver toxins be removed? Filtration and adsorption with the Prometheus system. Ther Apher Dial 2006; 10: 125-131.
4. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006; 10: 108-117.
5. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12(Suppl.) 17: S75-S82.
6. Nadalin S, Heuer M, Wallot M, Auth M, Schaffer R, Soti-ropoulos GC, Ballauf A, et al. Paediatric acute liver failure and transplantation: the University of Essen experience. Transpl Int 2007; 20: 519-527.
7. Yuan JZ, Ye QF, Zhao LL, Ming YZ, Sun H, Zhu SH, Huang ZF, et al. Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 2006; 12: 5055-5059.
8. Gaspari R, Avolio AW, Zileri Dal Verme L, Agnes S, Proiet-ti R, Castagneto M, Gasbarrini A. Molecular adsorbent recirculating system in liver transplantation: Safety and efficacy. Transplant Proc 2006; 38: 3544-3551.
9. Chiu A, Chan LM, Fan ST. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Liver Int 2006; 26: 695-702.
10. Stefoni S, Colì L, Bolondi L, Donati G, Ruggeri G, Feli-ciangeli G, Piscaglia F, et al. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int J Artif Organs 2006; 29: 207-218.
11. Novelli G, Rossi M, Pretagostini M, Pugliese F, Ruberto F, Novelli L, Nudo F, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 2005; 37: 2557-2559.
12. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958.
13. Di Campli C, Santoro MC, Gaspari R, Merra G, Zileri Dal Verme L, Zocco MA, et al. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 2005; 37: 2547-2550.
14. Mitzner S, Stange J, Dillmann A, Winkler RE, Michelsen A, Knippel M, Schmidt R. Removal of protein-bound uremic toxins by albumin dialysis: in vivo results. Nephrol Dial Transplant 1999; 14: A201.
15. Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, Zhang WY, et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003; 23(Suppl. 3): 16-20.
16. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-1119.
17. Kurtovic J, Boyle M, Bihari D, Riordan SM. Nitric-oxide-lowering effect of terlipressin in decompensated cirrhosis: comparison to the molecular adsorbent recirculating system and correlation with clinical status. Eur J Gas-troenterol Hepatol 2004; 16: 1335-1338.
18. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.
19. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Internat J Artif Organs 1996; 19: 677-691.
20. Stadlbauer V, Krisper P, Beuers U, Haditsch B, Sch-neditz D, Jung A, et al. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J 2007; 53: 187-193.
21. Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballau-ff A, Wallot M, et al. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 2005; 40: 54-59.
22. Isoniemi H, Koivusalo AM, Repo H, Ilonen I, Höckerstedt K. The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 2005; 37: 1088-1090.
23. Di Campli C, Zocco MA, Gaspari R, Novi M, Candelli M, Santoliquido A, Flore R, et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005; 37: 2551-2553.
24. Ilonen I, Koivusalo AM, Höckerstedt K, Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 2006; 38: 3540-3543.
25. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10: R169.
26. Klammt S, Mitzner S, Stange J, Brinkmann B, Drewelow B, Emmrich J, Liebe S, et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gas-troenterol Hepatol 2007; 19: 257-263.
27. Klammt S, Mitzner SR, Stange J, Loock J, Heemann U, Emmrich J, Reisinger EC, et al. Improvement of Albumin Binding Capacity is associated with improved survival in patients with decompensated liver cirrhosis. Liver Transpl 2008; 14: 1333-1339.
28. Mitzner S, Loock J, Peszynski P, Klammt S, Majcher-Peszynska J, Gramowski A, Stange J, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS-a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17: 463-475.
29. Hetz H, Faybik P, Berlakovich G, Baker A, Bacher A, Burghuber C, Sandner SE, et al. Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: a pilot study. Liver Transpl 2006; 12: 1357-1364.
30. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hype-racute liver failure: a prospective controlled trial. Liver Transpl 2003; 9: 290-297.
31. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepa-tol 2005; 43: 142-148.
32. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic ence-phalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862.
33. Camus C, Lavoué S, Gacouin A, Compagnon P, Boudjéma K, Jacquelinet C, Thomas R, et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial 2009; 13: 549-555.
34. Sen S, Rose C, Ytrebø LM, Davies NA, Nedredal GI, Dre-vland SS, Kjønnø M, et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006; 34: 158-164.
35. Mitzner SR. Drain the brain: albumin dialysis for intra-cranial hypertension. Crit Care Med 2006; 34: 254-255.
36. Saich R, Collins P, Ala A, Standish R, Hodgson H. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005; 17: 585-588.
37. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286.
38. Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 338-348.
39. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 111-123.
40. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gas-troenterol Hepatol 2007; 4: 43-51.
41. Mitzner SR. Albumin dialysis: an update. Curr Opin Ne-phrol Hypertens 2007; 16: 589-595.
42. Koivusalo AM, Vakkuri A, Höckerstedt K, Isoniemi H. Experience of Mars therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc 2005; 37: 3315-3317.
43. Braun C, Birck R, Singer MV, Schnuelle P, van der Woude FJ, Löhr M, et al. Life-threatening intoxication with methylene bis(thiocyanate): clinical picture and pitfalls. A case report. BMC Emerg Med 2006; 6: 5.
44. Liu YH, Wang Y, Yu LX, Sun LY, Feng BL, Shen ZY, Wang MM. Artificial liver support molecular adsorbents recirculating system therapy as a bridge to re-transplantation in two cases of long anhepatic duration. Hepatobiliary Pancreat Dis Int 2004; 3: 316-317.
45. Choi JY, Bae SH, Yoon SK, Cho SH, Yang JM, Han JY, Ahn BM, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation -a pilot study. Liver Int 2005; 25: 740-745.
46. Doria C, Mandalá L, Scott VL, Gruttadauria S, Marino IR. Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: a single-center experience. Dig Dis Sci 2006; 51: 47-53.
47. Trittenwein G, Boigner H, Mostafa G, Burda G, Mühl A, Amann G, Pollak A. Bridging to transplantation in acute liver failure in a 7-month-old infant. Wien Klin Wochens-chr 2006; 118: 298-301.
48. Wai CT, Lim SG, Aung MO, Lee YM, Sutedja DS, Dan YY, Aw MM, et al. MARS: a futile tool in centres without active liver transplant support. Liver Int 2007; 27: 69-75.
49. Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10: 107-114.
50. Montero JL, Pozo JC, Barrera P, Fraga E, Costán G, Do-mínguez JL, Muntané J, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006; 38: 2511-2513.
51. Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307-312.
52. Pichon N, François B, Chevreuil C, Gaulier JM. Albumin dialysis: a new therapeutic alternative for severe diltia-zem intoxication. Clin Toxicol (Phila) 2006; 44: 195-196.
53. Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005; 25: 973-977.
54. Lionte C, Sorodoc L, Simionescu V. Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). Rom J Gastroenterol 2005; 14: 267-271.
55. El Banayosy A, Kizner L, Schueler V, Bergmeier S, Co-baugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50: 332-337.
56. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289: 217-222.
57. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003; 23(Suppl. 3): 66-72.
58. Hessel FP, Bramlage P, Wasem J, Mitzner SR. Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol 2010; 22(2): 213-220.
59. Kantola T, Mäklin S, Koivusalo AM, Räsänen P, Rissanen A, Roine R, Sintonen H, et al. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010; 16: 2227-2234.
60. Drexler K, Baustian C, Richter G, Ludwig J, Ramlow W, Mitzner S. Albumin dialysis molecular adsorbents recirculating system: impact of dialysate albumin concentration on detoxification efficacy. Ther Apher Dial 2009; 13: 393-398.
61. Faybik P, Bacher A, Kozek-Langenecker SA, Steltzer H, Krenn CG, Unger S, Hetz H. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006; 10: R24.